Model-Informed Drug Discovery and Development (MID3): Transforming strategic decision making in oncology

Application of QSP in support of translational studies, next-generation MABEL FIH dose estimation and design of early clinical trials.

Discussion of modeling application for support of rational design of late-phase clinical trials.

How mechanistic PK/PD modeling and Model-Based Meta-Analysis support dose finding and personalization in the framework of “Project Optimus” initiative.